Sorafenib for the treatment of multiple myeloma

References

• San Miguel J. Multiple myeloma: a model for scientific and clinical progress. Hematology Am Soc Hematol Educ Program. 2014;2014:1–7.
   PubMed Web of Science ®Google Scholar
• National Cancer Institute. Surveillance epidemiology and end results program. SEER stat fact sheets on multiple myeloma. 2013 [cited 2013 Apr 24]. Available from: http://seer.cancer.gov/statfacts/html/mulmy.html
   Google Scholar
• Andrews SW, Kabrah S, May JE, et al. Multiple myeloma: the bone marrow microenvironment and its relation to treatment. Br J Biomed Sci. 2013;70:110–120.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005;352:2487–2498.
   PubMed Web of Science ®Google Scholar
• Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 1999;341:1565–1571.
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Hayman SR, Lacy MQ, et al. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood. 2005;106:4050–4053.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Blood E, Mitsiades CS, et al. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood. 2006;108:3458–3464.
   PubMed Web of Science ®Google Scholar
• Röllig C, Knop S, Bornhäuser M. Multiple myeloma. Lancet. 2015;385:2197–2208.
   PubMed Web of Science ®Google Scholar
• Morgan GJ, Davies FE, Gregory WM, et al. First-line and ongoing treatment with zoledronic acid improves overall survival in patients with multiple myeloma: results of the MRC IX randomised controlled trial. Lancet. 2010;376:1989–1999.
   PubMed Web of Science ®Google Scholar
• Mikhael JR, Dingli D, Roy V, et al. Management of newly diagnosed symptomatic multiple myeloma: updated mayo stratification of myeloma and risk-adapted therapy (mSMART) consensus guidelines 2013. Mayo Clin Proc. 2013;88:360–376.
   PubMed Web of Science ®Google Scholar
• Rajkumar SV. Myeloma today: disease definitions and treatment advances. Am J Hematol. 2015 Nov 13. doi:10.1002/ajh.24236. [Epub ahead of print].
   Web of Science ®Google Scholar
• Kumar SK, Lee JH, Lahuerta JJ, et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia. 2012;26:149–157.
   PubMed Web of Science ®Google Scholar
• San Miguel J, Weisel K, Moreau P, et al. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncol. 2013;14:1055–1066.
   PubMed Web of Science ®Google Scholar
• Lacy MQ, Hayman SR, Gertz MA, et al. Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM). Leukemia. 2010;24:1934–1939.
   PubMed Web of Science ®Google Scholar
• Shah JJ, Stadtmauer EA, Abonour R, et al. Phase I/II dose expansion of a multi-center trial of carfilzomib and pomalidomide with dexamethasone (Car-Pom-d) in patients with relapsed/refractory multiple myeloma. Blood. 2013;122:690.
   Web of Science ®Google Scholar
• Larocca A, Montefusco V, Bringhen S, et al. Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label study. Blood. 2013;122:2799–2806.
   PubMed Web of Science ®Google Scholar
• Mark TM, Boyer A, Rossi AC, et al. Clapd (clarithromycin, pomalidomide, dexamethasone) therapy in relapsed or refractory multiple myeloma. Blood (ASH Annual Meeting). 2013;122:1955.
   Web of Science ®Google Scholar
• Vij R, Siegel DS, Jagannath S, et al. An open label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib. Br J Haematol. 2012;158:739–748.
   PubMed Web of Science ®Google Scholar
• Siegel D, Martin T, Nooka A, et al. Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies. Haematologica. 2013;98:1753–1761.
   PubMed Web of Science ®Google Scholar
• Kaufman J, Zimmerman T, Jakubowiak A, et al. Phase I study of combination of carfilzomib and panabinostat for patients with relapsed and refractory myeloma: a multicenter MMRC clinical trial. Haematologica (EHA Annual Meeting). 2013;98(suppl 1):322.
   Google Scholar
• Shah JJ, Weber DM, Thomas SK, et al. Phase 1 study of the novel kinesin spindle protein inhibitor ARRY-520 1 carfilzomib in patients with relapsed and/or refractory multiple myeloma. Blood. 2012;120:4082.
   PubMed Web of Science ®Google Scholar
• Vesole DH, Siegel DSD, Richter JR, et al. A phase I study of carfilzomib, lenalidomide, vorinostat, and dexamethasone (QUAD) in relapsed and/or refractory multiple myeloma (MM). J Clin Oncol (ASCO Annual Meeting). 2014;32:8535.
   Google Scholar
• Bringhen S, Petrucci MT, Larocca A, et al. Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study. Blood. 2014;124:63–69.
   PubMed Web of Science ®Google Scholar
• Shah JJ, Stadtmauer EA, Abonour R, et al. Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma. Blood. 2015;126:2284–2290.
   PubMed Web of Science ®Google Scholar
• Hideshima T, Bradner JE, Wong J, et al. Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proc Natl Acad Sci U S A. 2005;102:8567–8572.
   PubMed Web of Science ®Google Scholar
• San-Miguel JF, Richardson PG, Gunther A, et al. Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myeloma. J Clin Oncol. 2013;31:3696–3703.
   PubMed Web of Science ®Google Scholar
• San-Miguel JF, Hungria VTM, Yoon S. Randomized phase 3 trial of the deacetylase inhibitor panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in relapsed or relapsed and refractory multiple myeloma. Lancet Oncol. 2014;15:1195–1206.
   PubMed Web of Science ®Google Scholar
• Lonial S, Vij R, Harousseau JL, et al. Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma. J Clin Oncol. 2012;30:1953–1959.
   PubMed Web of Science ®Google Scholar
• Jakubowiak AJ, Benson DM, Bensinger W, et al. Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed/refractory multiple myeloma. J Clin Oncol. 2012;30:1960–1965.
   PubMed Web of Science ®Google Scholar
• Lonial S, Dimopoulos M, Palumbo A, et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med. 2015;373:621–631.
   PubMed Web of Science ®Google Scholar
• Lonial S, Weiss BM, Usmani SZ, et al. Phase II study of daratumumab (DARA) monotherapy in patients with ≥ 3 lines of prior therapy or double refractory multiple myeloma (MM): MMY2002 (Sirius). J Clin Oncol (ASCO Annual Meeting). 2015;33:LBA8512.
   Google Scholar
• Plesner T, Arkenau T, Lokhorst H, et al. Preliminary safety and efficacy data of daratumumab in combination with lenalidomide and dexamethasone in relapsed or refractory multiple myeloma. Blood (ASH Annual Meeting). 2014;124:184.
   PubMed Web of Science ®Google Scholar
• Gentile M, Offidani M, Vigna E, et al. Ixazomib for the treatment of multiple myeloma. Expert Opin Investig Drugs. 2015;24:1287–1298.
   PubMed Web of Science ®Google Scholar
• Moreau P, Masszi T, Grzasko N, et al. Ixazomib, an investigational oral proteasome inhibitor (PI), in combination with lenalidomide and dexamethasone (IRd), significantly extends progression-free survival (PFS) for patients (Pts) with relapsed and/or refractory multiple myeloma (RRMM): the phase 3 tourmaline-MM1 study (NCT01564537). Blood (ASH Annual Meeting). 2015;125:727.
   Google Scholar
• Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004;64:7099–7109.
   PubMed Web of Science ®Google Scholar
• Yu C, Rahmani M, Almenara J, et al. Induction of apoptosis in human leukemia cells by the tyrosine kinase inhibitor adaphostin proceeds through a RAF-1/MEK/ERK- and AKT-dependent process. Oncogene. 2004;23:1364–1376.
   PubMed Web of Science ®Google Scholar
• Panka DJ, Wang W, Atkins MB, et al. The Raf inhibitor BAY 43-9006 (Sorafenib) induces caspase-independent apoptosis in melanoma cells. Cancer Res. 2006;66:1611–1619.
   PubMed Web of Science ®Google Scholar
• Rahmani M, Davis EM, Bauer C, et al. Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation. J Biol Chem. 2005;280:35217–35227.
   PubMed Web of Science ®Google Scholar
• Wan PT, Garnett MJ, Roe SM, et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell. 2004;116:855–867.
   PubMed Web of Science ®Google Scholar
• Carlomagno F, Anaganti S, Guida T, et al. BAY 43-9006 inhibition of oncogenic RET mutants. J Natl Cancer Inst. 2006;98:326–334.
   PubMed Web of Science ®Google Scholar
• Agency EMA. Sorafenib (Nexavar): summary of product characteristics (online). Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000690/WC500027704.pdf
   Google Scholar
• Yordanova A, Hose D, Neben K, et al. Sorafenib in patients with refractory or recurrent multiple myeloma. Hematol Oncol. 2013;31:197–200.
   PubMed Web of Science ®Google Scholar
• Srkalovic G, Hussein MA, Hoering A, et al. A phase II trial of BAY 43-9006 (sorafenib) (NSC-724772) in patients with relapsing and resistant multiple myeloma: SWOG S0434. Cancer Med. 2014;3:1275–1283.
   PubMed Web of Science ®Google Scholar
• Flaherty KT, Redlinger M, Schuchter LM, et al. Phase I/II, pharmacokinetic and pharmacodynamics trial of BAY 43-9006 alone in patients with metastatic melanoma. J Clin Oncol. 2005;23(16S):3037.
   Google Scholar
• Rini BI. Sorafenib. Expert Opin Pharmacother. 2006;7:453–461.
   PubMed Web of Science ®Google Scholar
• Lathia C, Lettieri J, Cihon F, et al. Lack of effect of ketoconazole-mediated CYP3A inhibition on sorafenib clinical pharmacokinetics. Cancer Chemother Pharmacol. 2006;57:685–692.
   PubMed Web of Science ®Google Scholar
• Hideshima T, Anderson KC. Novel therapies in MM: from the aspect of preclinical studies. Int J Hematol. 2011;94:344–354.
   PubMed Web of Science ®Google Scholar
• Ramakrishnan V, Timm M, Haug JL, et al. Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugs. Oncogene. 2010;29:1190–1202.
   PubMed Web of Science ®Google Scholar
• Chapman MA, Lawrence MS, Keats JJ, et al. Initial genome sequencing and analysis of multiple myeloma. Nature. 2011;471:467–472.
   PubMed Web of Science ®Google Scholar
• Chng WJ, Gonzalez-Paz N, Price-Troska T, et al. Clinical and biological significance of RAS mutations in multiple myeloma. Leukemia. 2008;22:2280–2284.
   PubMed Web of Science ®Google Scholar
• Bezieau S, Devilder MC, Avet-Loiseau H, et al. High incidence of N and K-Ras activating mutations in multiple myeloma and primary plasma cell leukemia at diagnosis. Hum Mutat. 2001;18:212–224.
   PubMed Web of Science ®Google Scholar
• Kharaziha P, De Raeve H, Fristedt C, et al. Sorafenib has potent antitumor activity against multiple myeloma in vitro, ex vivo, and in vivo in the 5T33MM mouse model. Cancer Res. 2012;72:5348–5362.
   PubMed Web of Science ®Google Scholar
• Udi J, Schüler J, Wider D, et al. Potent in vitro and in vivo activity of sorafenib in multiple myeloma: induction of cell death, CD138-downregulation and inhibition of migration through actin depolymerization. Br J Haematol. 2013;161:104–116.
   PubMed Web of Science ®Google Scholar
• Ramírez-Labrada A, López-Royuela N, Jarauta V, et al. Two death pathways induced by sorafenib in myeloma cells: Puma-mediated apoptosis and necroptosis. Clin Transl Oncol. 2015;17:121–132.
   PubMed Web of Science ®Google Scholar
• Kharaziha P, Ceder S, Sanchez C, et al. Multitargeted therapies for multiple myeloma. Autophagy. 2013;9:255–257.
   PubMed Web of Science ®Google Scholar
• Leow CCY, Gerondakis S, Spencer A. MEK inhibitors as a chemotherapeutic intervention in multiple myeloma. Blood Cancer J. 2013;3:e105.
   PubMed Web of Science ®Google Scholar
• Kumar SK, Jett J, Marks R, et al. Phase 1 study of sorafenib in combination with bortezomib in patients with advanced malignancies. Invest New Drugs. 2013;31:1201–1206.
   PubMed Web of Science ®Google Scholar
• Mangana J, Levesque MP, Karpova MB, et al. Sorafenib in melanoma. Expert Opin Investig Drugs. 2012;21:557–568.
   PubMed Web of Science ®Google Scholar
• Kumar S, Porrata LF, Ansell SM, et al. Phase 1 trial of sorafenib and everolimus in patients with lymphoma or multiple myeloma. Blood (ASH Annual Meeting). 2010;116:2802.
   Google Scholar
• Mayo Clinic; University of Iowa. Sorafenib and everolimus in treating patients with relapsed or refractory lymphoma or multiple myeloma (NCT00474929). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000 [cited 2007 May 16]. Available from: https://clinicaltrials.gov/ct2/show/NCT00474929? term=sorafenib+myeloma&rank=1 Identifier: NCT00474929.
   Google Scholar
• SCRI Development Innovations, LLC; Bayer. Sorafenib and bortezomib treatment for relapsed or refractory multiple myeloma patients (NCT00536575). Bethesda (MD): National Library of Medicine (US). 2000 [cited 2007 Sep 26]. Available from: https://clinicaltrials.gov/ct2/show/NCT00536575?term=sorafenib+myeloma&rank=2 Identifier: NCT00536575.
   Google Scholar
• National Cancer Institute (NCI). Sorafenib in treating patients with relapsed or refractory multiple myeloma (NCT00253578). Bethesda (MD): National Library of Medicine (US). 2000 [cited 2005 Nov 11]. Available from: https://clinicaltrials.gov/ct2/show/NCT00253578?term=sorafenib+myeloma&rank=3 Identifier: NCT00253578.
   Google Scholar
• Mayo Clinic; National Cancer Institute (NCI). Sorafenib, lenalidomide, and dexamethasone in treating patients with relapsed or refractory multiple myeloma (NCT00687674). Bethesda (MD): National Library of Medicine (US).. 2000 [cited 2008 May 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT00687674?term=sorafenib+myeloma&rank=4 Identifier: NCT00687674.
   Google Scholar
• National Cancer Institute (NCI). Sorafenib in treating patients with metastatic or unresectable solid tumors, multiple myeloma, or Non-Hodgkin’s lymphoma with or without impaired liver or kidney function (NCT00118170). Bethesda (MD): National Library of Medicine (US). 2000 [cited 2008 Jul 11]. Available from: https://clinicaltrials.gov/ct2/show/NCT00118170?term=sorafenib+myeloma&rank=5 Identifier: NCT00118170.
   Google Scholar
• National Cancer Institute (NCI). Sorafenib and bortezomib in treating patients with advanced cancer (NCT00303797). Bethesda (MD): National Library of Medicine (US). 2000 [cited 2006 Mar 15]. Available from: https://clinicaltrials.gov/ct2/show/NCT00303797?term=sorafenib+myeloma&rank=6 Identifier: NCT00303797.
   Google Scholar